We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other AI stocks in news and ratings you should not miss.
AI Expansion Continues as Startups Receive Major Funding Rounds
On February 19, CNBC reported significant funding rounds for multiple AI-focused startups, highlighting the quick expansion of AI innovations across industries like healthcare, cloud computing, and model deployment. Baseten, a San Francisco-based company founded in 2019, raised $75 million at an $825 million valuation to improve its AI model deployment services. Using cloud infrastructure from Amazon and Google, Baseten helps clients access GPUs for AI inference, reducing costs by over 40% while supporting the cost-effective DeepSeek-R1 reasoning model. Its revenue increased sixfold in the last fiscal year, and its clients include over 100 enterprises and companies such as Descript, Patreon, and Writer.
OpenEvidence, an AI health-tech startup in Cambridge founded by Daniel Nadler, raised $75 million from Sequoia, bringing its valuation to $1 billion, as per CNBC. The company’s AI chatbot, trained on data from The New England Journal of Medicine and peer-reviewed journals, assists doctors with clinical decisions and is already used by a quarter of U.S. physicians. The chatbot avoids inaccuracies through tailored training and has grown rapidly due to word-of-mouth recommendations among doctors. OpenEvidence will also use its new funding to establish partnerships, including one with NEJM Group, and Nadler views the company as a solution to doctor burnout and the projected physician shortfall.
Lambda, a cloud computing firm specializing in AI development, raised $480 million in a Series D round co-led by Andra Capital and SGW, reaching a $2.5 billion valuation and total funding of $863 million. Lambda rents out Nvidia GPU-powered servers and offers software to train and deploy AI models, including open-source ones like DeepSeek-R1. CEO Stephen Balaban highlighted Lambda’s ability to repurpose its 25,000 GPUs for open-source AI models, which has fueled demand for H200 chips. The company will use the funding to expand its GPU inventory and further develop its software, including its Model Inference API and Chat AI Assistant. Lambda is positioned to meet the surging demand for AI infrastructure and is serving over 5,000 customers across industries such as manufacturing and finance,
For this article, we selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey’s Q4 database of over 1000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Copyright: nexusplexus / 123RF Stock Photo
Tempus AI, Inc. (NASDAQ:TEM)
Number of Hedge Fund Holders: 17
Tempus AI, Inc. (NASDAQ:TEM) provides healthcare technology solutions, including diagnostic testing, clinical trial matching, data analytics, and AI-driven platforms for healthcare and pharmaceutical industries.
On February 19, Tempus AI, Inc. (NASDAQ:TEM) secured $300 million in additional debt financing from Ares Management’s Credit funds to support its acquisition of Ambry Genetics, finalized on February 3, 2025. It brings Ares’ total funding for Tempus to approximately $560 million since 2022. Tempus uses AI and data-driven technology to improve clinical care and research and the management emphasized that this investment will help drive innovation in precision medicine. The company views the funding as crucial for advancing its technological solutions and improving patient outcomes across oncology, cardiology, and other medical fields. Douglas Dieter, Dr.P.H., Partner in the Ares Credit Group commented:
“Over the last two years, we’ve been impressed by the Tempus team’s execution of its growth strategy and complementary acquisition of Ambry, and we look forward to further supporting their efforts in AI-enabled solutions that help advancements in medicine.”
Overall, TEM ranks 7th on our list of the AI stocks in news and ratings you should not miss. While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TEM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.